2023-505279-62-00招募中2 期
A Phase 1/2a Study of Safety, Pharmacokinetics and Neutralizing Activity of SPK002 as pre-exposure prophylaxis of COVID-19 in healthy volunteers (Phase 1) and immunocompromised individuals (Phase 2a).
Spikimm1 个研究点 分布在 1 个国家目标入组 78 人开始时间: 2023年7月3日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 78
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Antoine Pau
Scientific
Spikimm
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy SubjectsNCT07300189OrsoBio, Inc332
招募中
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination with Palbociclib and/or LHRH Agonist in Patients with Locally Advanced or Metastatic Estrogen Receptor−Positive Breast Cancer2023-506700-12-00Genentech Inc.45
招募中
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients with Advanced or Metastatic Prostate Cancer2023-504013-68-00Genentech Inc.46
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors2023-504709-35-00Genentech Inc.44
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma2023-505212-38-00Genentech Inc.43